Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment

BMC Complementary and Alternative Medicine

Baojin Hua²  Rui Liu²  Ge Zhang²  Liang Geng⁴  Shakir M Saud¹  Cihui Chen³  Weidong Li² 

[1] Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD 21702, USA;Oncology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China;Oncology Department, Zhejiang Provincial Hospital of TCM, Hangzhou, Zhejiang 310006, China;Henan Cancer Hospital affiliated to Zhengzhou University, Zhengzhou, Henan 450003, China

关键词: Cyclophosphamide;    Epithelial mesenchymal transition;    Invasion;    Inflammation;    Nuclear factor kappa light chain enhancer of activated B cells;    Fei-Liu-Ping ointment;    Lung cancer;   

Others  :  1159796
DOI  :  10.1186/1472-6882-14-153

 received in 2013-10-05, accepted in 2014-04-29,  发布年份 2014

【 摘 要 】

Background

Lung cancer is one of the leading causes of cancer-related mortality worldwide. Conventional chemotherapy and radiotherapy are the primary therapeutic methods for lung cancer with the use of combination therapies gaining popularity. The frequency and duration of treatment, as well as, managing lung cancer by targeting multiple aspects of cancer biology is often limited by toxicity to the patient. There are many naturally occurring anticancer agents that have a high degree of efficacy and low toxicity, offering a viable and safe approach for the treatment of lung cancer. The herbs traditionally used in Chinese medicine for anticancer treatment offer great potential to enhance the efficacy of conventional therapy. In this study, we evaluated the synergistic effects of Fei-Liu-Ping (FLP) ointment in treating lung cancer; a known anticancer Chinese herbal based formula.

Methods

In this study, A549 human lung carcinoma cell line and Lewis lung carcinoma xenograft mouse model were used. In addition, we utilized an in vitro co-culture system to simulate the tumor microenvironment in order to evaluate the molecular mechanisms of FLP treatment.

Results

FLP treatment significantly inhibited tumor growth in the Lewis lung xenograft by 40 percent, compared to that of cyclophosphamide (CTX) of 62.02 percent. Moreover, combining FLP and CTX inhibited tumor growth by 83.23 percent. Upon evaluation, we found that FLP treatment reduced the concentration of serum pro-inflammatory cytokines IL-6, TNF-α, and IL-1β. In addition, we also found an improvement in E-cadherin expression and inhibition of N-cadherin and MMP9. We found similar findings in vitro when we co-cultured A549 cells with macrophages. FLP treatment inhibited A549 cell growth, invasion and metastasis, in part, through the regulation of NF-κB and altering the expression of E-cadherin, N-cadherin, MMP2 and MMP9.

Conclusions

FLP exerts anti-inflammatory properties in the tumor microenvironment, which may contribute to its anticancer effects. FLP treatment may be a promising therapy for inflammation associated lung cancer treatment alone, or in combination with conventional therapies and may prevent lung cancer metastasis.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):10-30.
• [2]Tang JM, He QY, Guo RX, Chang XJ: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006, 51(2):181-191.
• [3]Brekken RA, Thorpe PE: Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 2001, 21(6B):4221-4229.
• [4]Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, Sun J, Zhou L, Yao Y, Jiao L, Su W, Guo H, Chen P, Liu J: Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med 2012, 12:112. BioMed Central Full Text
• [5]Guo H, Liu JX, Xu L, Madebo T, Baak JP: Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther 2011, 10(2):127-137.
• [6]Wan C, You S, Quan P, Song Y, Liu T, Lu J, Zheng P: Development and validation of the quality-of-life assessment system for lung cancer based on traditional Chinese medicine. Evid Based Complement Altern Med 2012, 2012:945910.
• [7]Wong R, Sagar CM, Sagar SM: Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev 2001, 27(4):235-246.
• [8]Yang D, Tian G: Review of experimental study on treatment of lung cancer with traditional Chinese medicine. Zhongguo Zhong Yao Za Zhi 2009, 34(18):2405-2409.
• [9]Zhang P, Piao B, Sun G: Influence of feiliuping No. 2 on platelet surface glycoprotein expression in mid-late stage lung cancer patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000, 20(1):31-33.
• [10]Zheng HG, Piao BK, Hua BJ: Effect of feiliuping ointment and its disassembled prescriptions on dendritic cell of mice with transplanted Lewis lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010, 30(12):1288-1291.
• [11]Coussens LM, Zitvogel L, Palucka AK: Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013, 339(6117):286-291.
• [12]Candido J, Hagemann T: Cancer-related inflammation. J Clin Immunol 2013, 33(Suppl 1):S79-84.
• [13]Bochu W, Liancai Z, Qi C: Primary study on the application of serum pharmacology in Chinese traditional medicine. Colloids Surf B: Biointerfaces 2005, 43(3–4):194-197.
• [14]Cao Y, Zhang D, Zheng G, Zhang J: Study on effect of drug concentration of "Bushen huayu jiedu fang" drug serum on drug-resistance lung cancer cells with serum pharmacology. Zhong Yao Cai 2003, 26(4):263-265.
• [15]Plezia PM, Alberts DS, Peng YM, Xu MJ, Sayers S, Davis TP, Surwit EA, Meyskens FL Jr: The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. Prev Med 1989, 18(5):680-687.
• [16]Walther H, Meyer FP, Quednow B, Leuschner U, Kohler E, Horenburg I: Dosage monitoring through measurement of serum level–a task of clinical pharmacology. Int J Clin Pharmacol Biopharm 1978, 16(8):387-390.
• [17]Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee BN: Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003, 97(11):2919-2925.
• [18]Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Cleeland CS: A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 2004, 11(5):279-292.
• [19]Dantzer R: Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001, 15(1):7-24.
• [20]Rube CE, Wilfert F, Uthe D, Konig J, Liu L, Schuck A, Willich N, Remberger K, Rube C: Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol 2004, 72(2):231-241.
• [21]Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2(4):301-310.
• [22]Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2002, 2(10):725-734.
• [23]Birchmeier W, Birchmeier C: Epithelial-mesenchymal transitions in development and tumor progression. EXS 1995, 74:1-15.
• [24]Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17(5):548-558.
• [25]Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7(2):131-142.
• [26]Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25(1):9-34.
• [27]Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284(5751):67-68.
• [28]Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C: Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25(8):1543-1549.
• [29]Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005, 175(2):1197-1205.
• [30]Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6(3):203-208.
• [31]Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. in Cancer Res 2009, 15(2):425-430.
• [32]Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS: Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A 2007, 104(47):18514-18519.
• [33]Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, Fingleton B: Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res 2008, 6(3):364-371.
• [34]Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T: Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462(7269):104-107.
• [35]Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M: Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010, 17(1):89-97.
• [36]Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3(1):17-26.
• [37]Garg A, Aggarwal BB: Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16(6):1053-1068.
• [38]Zhang Y, Chen F: Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res 2004, 64(6):1902-1905.
• [39]Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3(3):221-227.
• [40]Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC: Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res 2012, 72(5):1290-1300.